Dr Pant on the Landscape-Changing Success of Daraxonrasib in Pancreatic Cancer

The oral multi-selective inhibitor daraxonrasib significantly outperformed investigator's choice chemotherapy as a second-line treatment for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial demonstrated a 60% reduction in the risk of death across both the primary mutation group and the overall study population. Here, Shubham Pant, MD, MBBS, discusses the findings in an interview at the 2026 ASCO Annual Meeting in Chicago, IL.

The dual primary end points of the study evaluated efficacy in patients harboring RAS G12 mutations, though benefits were uniformly confirmed across the entire population.

Beyond extending survival, daraxonrasib notably improved patient-reported outcomes. It delayed the time to pain deterioration to a median of 9.2 months compared with 3.8 months with chemotherapy. It also doubled the time before a patient's overall quality of life began to worsen (5.7 vs 2.6 months).

From a safety perspective, daraxonrasib proved more tolerable than traditional chemotherapy regimens:

• Grade 3 or higher treatment-related adverse events (TRAEs) were lower with daraxonrasib (43.6%) than with chemotherapy (57.5%).
• Only 1.2% of patients taking daraxonrasib discontinued treatment due to toxicity, compared to 11.2% on chemotherapy.
• The main drivers for dose adjustments with the oral inhibitor were skin rash and stomatitis (mouth sores), whereas chemotherapy routinely caused cytopenias (low blood counts), neuropathy, and fatigue.